Abstract
FGFs and their receptors (FGFRs) are critical for many biologic processes, including angiogenesis, wound healing and tissue regeneration. Aberrations in FGFR signaling are common in cancer, making FGFRs a promising target in antitumor studies. To date, many FGFR inhibitors are being detected in clinical studies, and resistance to some inhibitors has emerged. Understanding the mechanisms of resistance is a fundamental step for further implementation of targeted therapies. In this review, we will describe the basic knowledge regarding FGF/FGFR signaling and categorize the clinical FGFR inhibitors. The mechanisms of resistance to FGFR inhibitors and corresponding strategies of overcoming drug resistance will also be discussed.
Financial & competing interest disclosure
The authors of this review were supported by Excellent Science and Technology Innovation Team of Jiangsu Province in 2015, National Natural Science Foundation (No. 21172265), Jiangsu Provincial Natural Science Funding (2018), the State Key Laboratory of Medicinal Chemical Biology, Nankai University (No. 2018020) and Innovation Program for the Postgraduates in Jiangsu. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in this manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.